Antibiotic-associated diarrhea: potentials for the use of synbiotics

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Gastrointestinal disorders are the most common adverse drug reactions that occur during antibiotic therapy, often with the development of antibiotic-associated diarrhea (AAD). Antibiotics are believed to be the direct cause of one in four cases of drug-induced diarrhea. The first part of the review briefly provides basic information about the etiology, pathogenesis and clinical forms of AAD. The second part discusses the issues of normalization of intestinal microbiocenosis as an important aspect of the treatment and prevention of AAD. The effectiveness of probiotic strains increases when used together with prebiotics. The properties and capabilities of probiotic strains Bifidumbacterium lactis B l-04; Lactobacillus acidophilus La-14, Lactobacillus rhamnosus Lr-32, andtheir combination with the prebiotic inulin and B vitamins are discussed. The results of clinical studies of the synbiotic Floriosis, demonstrating its effectiveness and safety in restoring a balanced intestinal microbiota are presented.

Full Text

Restricted Access

About the authors

Dmitry I. Trukhan

Omsk State Medical University

Author for correspondence.
Email: dmitry_trukhan@mail.ru
ORCID iD: 0000-0002-1597-1876

Dr. Sci. (Med.), Associate Professor, Professor of the Department of Polyclinic Therapy and Internal Diseases

Russian Federation, Omsk

V. A. Gudilin

Omsk State Medical University

Email: dmitry_trukhan@mail.ru
Russian Federation, Omsk

References

  1. Козлов, С.Н., Козлов Р.С. Современная антимикробная химиотерапия: Руководство для врачей. 3-е изд., перераб. и доп. М.: ООО «МИА», 2017. 400 с. [Kozlov, S.N., Kozlov R.S. Modern antimicrobial chemotherapy: A guide for doctors. 3rd ed., revised. and additional M.: MIA LLC, 2017. 400 p. (In Russ.)]. URL: https://vk.com/wall-6557522_45553?ysclid=ll9qa2huqs950166790
  2. Захаренко С.М., Андреева И.В., Стецюк О.У. Нежелательные лекарственные реакции со стороны ЖКТ и антибиотикоассоциированная диарея при применении антибиотиков в амбулаторной практике: профилактика и лечение. Клиническая микробиология и антимикробная химиотерапия. 2019;3:196–206. doi: 10.36488/cmac.2019.3.196–206. [Zakharenko S.M., Andreeva I.V., Stetsyuk O.U. Adverse drug reactions from the gastrointestinal tract and antibiotic-associated diarrhea when using antibiotics in outpatient practice: prevention and treatment. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2019;3:196–206. (In Russ.)].
  3. Тарасова Л.В., Трухан Д.И. Болезни кишечника. Клиника, диагностика и лечение. СПб.: СпецЛит.; 2022. 222 с. [Tarasova L.V., Trukhan D.I. Intestinal diseases. Clinic, diagnosis and treatment. St Petersburg: SpecLit; 2022. 222 р. (In Russ.)]. URL: https://elibrary.ru/item.asp?id=49497776.
  4. Makins R., Ballinger A. Gastrointestinal side effects of drugs. Expert Opin Drug Saf. 2003;2(4):421–29. doi: 10.1517/14740338.2.4.421.
  5. Тарасова Л.В., Трухан Д.И. Лекарственная безопасность в гастроэнтерологии. Экспериментальная и клиническая гастроэнтерология. 2013;4:81–7. [Tarasova L.V., Trukhan D.I. Drug safety in gastroenterology. Eksperimental’naya i klinicheskaya gastroenterologiya. 2013;4:81–7. (In Russ.)].
  6. Giannelli F.R. Antibiotic-associated diarrhea. JAAPA. 2017;30(10):46–7. doi: 10.1097/01. JAA.0000524721.01579. c. 9.
  7. Фоминых Ю.А., Соусова Я.В. Практические рекомендации для терапевтов по диагностике и лечению антибиотикоассоциированной диареи. University Therapeutic Journal. 2021;3(3):15965. [Fominykh Yu.A., Sousova Ya.V. Practical recommendations for therapists on the diagnosis and treatment of antibiotic-associated diarrhea. University Therapeutic Journal. 2021;3(3):15965. (In Russ.)].
  8. McFarland L.V. Epidemiology, risk factors and treatments for antibiotic associated diarrhea. Dig Dis. 1998;16(5):292–307. doi: 10.1159/000016879.
  9. McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 2008;3(5):563–78. doi: 10.2217/17460913.3.5.563.
  10. Fine K.D., Schiller L.R. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999;116:1464–86. doi: 10.1016/S0016– 5085(99)70513–5.
  11. Каннер Е.В., Горелов А.В., Крутихина С.Б. Анти-биотикоассоциированная диарея у детей: современный взгляд на проблему. Медицин-ский совет. 2017;1:226–30. [Kanner E.V., Gorelov A.V., Krutikhina S.B. Antibiotic-associated diarrhea in children: a modern view of the problem. Meditsinskii sovet. 2017;1:226–30. (In Russ.)]. doi: 10.21518/2079-701X-2017-1-226-230.
  12. Cervantes J. Use your antibiotics wisely. Consequences to the intestinal microbiome. FEMS Microbiol Lett. 2016;363(10):fnw081. doi: 10.1093/femsle/fnw081.
  13. Hogenauer C., Hammer H.F., Krejs G.J., Reisinger E.C. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis. 1998;27(4):702–10. doi: 10.1086/514958.
  14. Varughese C.A., Vakil N.H., Phillips K.M. Antibiotic-associated diarrhea: a refresher on causes and possible prevention with probiotics--continuing education article. J Pharm Pract. 2013;26(5):476–82. doi: 10.1177/0897190013499523.
  15. de Nies L., Kobras C.M., Stracy M. Antibiotic-induced collateral damage to the microbiota and associated infections. Nat Rev Microbiol. 2023 Aug 4. doi: 10.1038/s41579-023-00936-9.
  16. Schröder O., Gerhard R., Stein J. Antibiotic-associated diarrhea. Z Gastroenterol. 2006;44(2):193–204. doi: 10.1055/s-2005-858978.
  17. Драпкина О.М., Лазебник Л.Б., Бакулин И.Г. и др. Инфекция Clostridioides difficile: диагностика, лечение и профилактика. Клинические рекомендации Российского научного медицинского общества терапевтов, Научного общества гастроэнтерологов России, Общества гастроэнтерологов и гепатологов «Северо-Запад». Экспериментальная и клиническая гастроэнтерология. 2023;210(2):4–32. [Drapkina O.M., Lazebnik L.B., Bakulin I.G. and others. Clostridioides difficile infection: diagnosis, treatment and prevention. Clinical recommendations of the Russian Scientific Medical Society of Therapists, Scientific Society of Gastroenterologists of Russia, Society of Gastroenterologists and Hepatologists “North-West”. Eksperimental’naya i klinicheskaya gastroenterologiya. 2023;210(2):4–32. (In Russ.)]. doi: 10.31146/1682-8658-ecg210-2-4-32.
  18. Шульпекова Ю.О. Антибиотикоассоци-ированная диарея. Русский медицинский журнал. 2007;15(6):467–73. [Shulpekova Yu.O. Antibiotic-associated diarrhea. Russkii meditsinskii zhurnal. 2007;15(6):467–73. (In Russ.)].
  19. Успенский Ю.П., Барышникова Н.В. Антибиотик-ассоциированная диарея в условиях стационара: частота встречаемости и вопросы профилактики. Медицинский алфавит. 2021;20:35–7. [Uspensky Yu.P., Baryshnikova N.V. Antibiotic-associated diarrhea in hospital settings: incidence and prevention issues. Meditsinskii alfavit. 2021;20:35–7. (In Russ.)]. doi: 10.33667/2078-5631-202120-35-37.
  20. Успенский Ю.П., Фоминых Ю.А. Антибиотик-ассоциированная диарея: актуальность проблемы, профилактика и терапия. Архив внутренней медицины. 2013;2(10):46–53. [Uspensky Yu.P., Fominykh Yu.A. Antibiotic-associated diarrhea: relevance of the problem, prevention and therapy. Arkhiv vnutrennei meditsiny. 2013;2(10):46–53. (In Russ.)].
  21. Успенский Ю., Барышникова Н. Дисбиоз кишечника и антибиотик-ассоциированная диарея в условиях стационара: профилактика и коррекция. Врач. 2019;30(12):81–5. [Uspensky Yu., Baryshnikova N. Intestinal dysbiosis and antibiotic-associated diarrhea in a hospital setting: prevention and correction. Vrach. 2019;30(12):81–5. (In Russ.)]. doi: 10.29296/25877305-2019-12-21.
  22. Казюлин А.Н., Гончаренко А.Ю., Павлеева Е.Е., Калягин И.Е. Эволюция терапии пробиотиками в клинике внутренних болезней. Русский медицинский журнал. 2019;12:89–96. [Kazyulin A.N., Goncharenko A.Yu., Pavleeva E.E., Kalyagin I.E. The evolution of probiotic therapy in the clinic of internal medicine. Russkii meditsinskii zhurnal. 2019;12:89–96. (In Russ.)].
  23. Трухан Д.И., Филимонов С.Н. Диффе-ренциальный диагноз основных симптомов и синдромов при заболеваниях желудочно-кишечного тракта. Новокузнецк, 2022. 234 с. [Trukhan D.I., Filimonov S.N. Differential diagnosis of the main symptoms and syndromes in diseases of the gastrointestinal tract. Novokuznetsk, 2022. 234 р. (In Russ.)]. URL: https://www.elibrary.ru/item.asp?id=48177755.
  24. Ардатская М.Д., Анучкин А.А., Буторова Л.И., Павлов А.И., Нугаева Н.Р., Фадина Ж.В. Патогенетические аспекты развития и лечения антибиотик-ассоциированной диареи: выбор синбиотика с позиции доказательной медицины. Медицинский совет. 2023;17(6):113–25. [Ardatskaya M.D., Anuchkin A.A., Butorova L.I., Pavlov A.I., Nugaeva N.R., Fadina Zh.V. Pathogenetic aspects of the development and treatment of antibiotic-associated diarrhea: choice of synbiotic from the perspective of evidence-based medicine. Meditsinskii sovet. 2023;17(6):113–25. (In Russ.)]. doi: 10.21518/ms2023-026.
  25. Motamedi H., Fathollahi M., Abiri R., et al. A worldwide systematic review and meta-analysis of bacteria related to antibiotic-associated diarrhea in hospitalized patients. PLoS One. 2021;16(12):e0260667. doi: 10.1371/journal.pone.0260667.
  26. Dahiya D., Nigam P.S. Antibiotic-Therapy-Induced Gut Dysbiosis Affecting Gut Microbiota-Brain Axis and Cognition: Restoration by Intake of Probiotics and Synbiotics. Int J Mol Sci. 2023;24(4):3074. doi: 10.3390/ijms24043074.
  27. Пробиотики и пребиотики. Всемирная гастроэнтерологическая организация (WGO). Практические рекомендации. 2008. (Электронный ресурс). URL: https://www.gastroscan.ru/literature/authors/5634 (дата обращения 15.08.2023). [Probiotics and prebiotics. World Gastroenterology Organization (WGO). Practical recommendations. 2008. (Electronic resource). URL: https://www.gastroscan.ru/literature/authors/5634 (access date 08/15/2023). (In Russ.)].
  28. Трухан Д.И., Филимонов С.Н. Диф-ференциальный диагноз основных гастроэнтерологических синдромов и симптомов. М., 2016:168 с. [Trukhan D.I., Filimonov S.N. Differential diagnosis of major gastroenterological syndromes and symptoms. Мoscow, 2016. 168 р. (In Russ.)]. URL: https://www.gastroscan.ru/literature/authors/13898.
  29. Трухан Д.И., Филимонов С.Н. Заболевания кишечника: клиника, диагностика и лечение. Новокузнецк, 2017. 223 с. [Trukhan D.I., Filimonov S.N. Intestinal diseases: clinic, diagnosis and treatment. Novokuznetsk, 2017. 223 р. (In Russ.)].
  30. Казюлин А.Н., Гончаренко А.Ю., Павлеева Е.Е., Калягин И.Е. Эволюция терапии пробиотиками в клинике внутренних болезней. Русский медицинский журнал. 2019;12:89–96. [Kazyulin A.N., Goncharenko A.Yu., Pavleeva E.E., Kalyagin I.E. The evolution of probiotic therapy in the clinic of internal medicine. Russkij meditsinskij zhurnal. 2019;12:89–96. (In Russ.)].
  31. Голошубина В.В., Трухан Д.И., Багишева Н.В. Нарушения кишечного микробиоценоза: актуальные аспекты терминологии, клиники, профилактики. Русский медицинский журнал. 2020;12:17–22. [Goloshubina V.V., Trukhan D.I., Bagisheva N.V. Disorders of intestinal microbiocenosis: current aspects of terminology, clinic, prevention. Russkij meditsinskij zhurnal. 2020;12:17–22. (In Russ.)].
  32. Трухан Д.И. Нарушения кишечного микробиоценоза: расширение сферы применения пробиотиков. Медицинский совет. 2022;7:132–43. [Trukhan D.I. Disorders of intestinal microbiocenosis: expanding the scope of use of probiotics. Meditsinskii sovet. 2022;7:132–43. (In Russ.)]. doi: 10.21518/2079-701X-2022-16-7-132-143.
  33. Surawicz C.M. Role of probiotics in antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2008;42 Suppl 2:S64–70. doi: 10.1097/MCG.0b013e3181646d09.
  34. World Gastroenterology Organisation practice guideline: Probiotics and prebiotics. Arab J Gastroenterol. 2009;10(1):33–42. doi: 10.1016/j.ajg.2009.03.001.
  35. Guarner F., Khan A.G., Garisch J., et al. World Gastroenterology Organization. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol. 2012;46(6):468–81. doi: 10.1097/MCG.0b013e3182549092.
  36. Quigley E.M. Prebiotics and probiotics: their role in the management of gastrointestinal disorders in adults. Nutr Clin Pract. 2012;27(2):195–200. doi: 10.1177/0884533611423926.
  37. Ивашкин В.Т., Ющук Н.Д., Маев И.В. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению Clostridium difficile-ассоциированной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;5:56–65. [Ivashkin V.T., Yushchuk N.D., Maev I.V. and others. Recommendations of the Russian Gastroenterological Association for the diagnosis and treatment of Clostridium difficile-associated disease. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2016;5:56–65. (In Russ.)].
  38. Ивашкин В.Т., Маев И.В., Абдулганиева Д.И. и др. Практические рекомендации Научного сообщества по содействию клиническому изучению микробиома человека (НСОИМ) и Российской гастроэнтерологической ассоциации (РГА) по применению пробиотиков для лечения и профилактики заболеваний гастроэнтерологического профиля у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(2):76–89. [Ivashkin V.T., Maev I.V., Abdulganieva D.I. etc. Practical recommendations of the Scientific Community for Promoting the Clinical Study of the Human Microbiome (NSOM) and the Russian Gastroenterological Association (RGA) on the use of probiotics for the treatment and prevention of gastroenterological diseases in adults. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2020;30(2):76–89. (In Russ.)]. doi: 10.22416/1382-43762020-30-2-76-89.
  39. Wilson A.S., Koller K.R., Ramaboli M.C., et al. Diet and the Human Gut Microbiome: An International Review. Dig Dis Sci. 2020;65(3):723–40. doi: 10.1007/s10620-020-06112-w.
  40. Goldenberg J.Z., Ma S.S., Saxton J.D., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013;(5):CD006095. doi: 10.1002/14651858.CD006095.pub3.
  41. Hayes S.R., Vargas A.J. Probiotics for the Prevention of Pediatric Antibiotic-Associated Diarrhea. Explore (NY). 2016;12(6):46366– doi: 10.1016/j.explore.2016.08.015.
  42. Preidis G.A., Weizman A.V., Kashyap P.C., Morgan R.L. AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020;159(2):708–738.e4. Doi: 10.1053/j. gastro.2020.05.060.
  43. Su G.L., Ko C.W., Bercik P., et al. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020;159(2):697–705. doi: 10.1053/j.gastro.2020.05.059.
  44. Su G.L., Ko C.W., Bercik P., et al. Spotlight: Probiotics Guidelines. Gastroenterology. 2020;159(2):707. doi: 10.1053/j.gastro.2020.07.025.
  45. Liao W., Chen C., Wen T., Zhao Q. Probiotics for the Prevention of Antibiotic-associated Diarrhea in Adults: A Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Gastroenterol. 2021;55(6):469–80. doi: 10.1097/MCG.0000000000001464.
  46. McFarland LV. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe. 2009;15(6):274–80. doi: 10.1016/j.anaerobe.2009.09.002.
  47. Pandey K.R., Naik S.R., Vakil B.V. Probiotics, prebiotics and synbiotics – a review. J Food Sci Technol. 2015;52(12):7577–87. doi: 10.1007/s13197-015-1921-1.
  48. Gueimonde M., Ouwehand A.C., Salminen S. Safety of probiotics. Scandinavian J Nutr. 2004;48(1):42–8. doi: 10.3402/fnr.v48i1.1502.
  49. Cox A.J., West N.P., Horn P.L., et al. Effects of probiotic supplementation over 5 months on routine haematology and clinical chemistry measures in healthy active adults. Eur J Clin Nutr. 2014;68(11):1255–57. doi: 10.1038/ejcn.2014.137.
  50. Хавкин А.И., Комарова О.Н. Эффективность поликомпонентных пробиотических препаратов, включающих штаммы Lactobacillus acidophilus LA-14, Lactobacillus reuteri и Bifidobacterium lactis при функциональных нарушениях пищеварения у детей раннего возраста: результаты проспективного, открытого, наблюдательного исследования. Экспериментальная и клиническая гастроэнтерология. 2017;141(5):57–64. [Khavkin A.I., Komarova O.N. The effectiveness of polycomponent probiotics including strains of lactobacillus acidophilus la-14, lactobacillus reuteri and bifidobacterium lactis in functional gastrointestinal disorders in early aged children: the results of a prospective, open, observational study. Eksperimental’naya i Klinicheskaya Gastroenterologiya. 2017;141(5):57–64. (In Russ.)].
  51. Barker A.K., Duster M., Valentine S., et al. A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO). J Antimicrob Chemother. 2017;72(11):3177–80. doi: 10.1093/jac/dkx254.
  52. Miyazima T.Y., Ishikawa K.H., Mayer M., et al. Cheese supplemented with probiotics reduced the Candida levels in denture wearers-RCT. Oral Dis. 2017;23(7):919-925. doi: 10.1111/odi.12669.
  53. De Wolfe T.J., Eggers S., Barker A.K., et al. Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection. PLoS One. 2018;13(9):e0204253. doi: 10.1371/journal.pone.0204253.
  54. Gomes A.C., Hoffmann C., Mota J.F. Gut microbiota is associated with adiposity markers and probiotics may impact specific genera. Eur J Nutr. 2019 Jun 27. doi: 10.1007/s00394-019-02034-0
  55. Airaksinen K., Yeung N., Lyra A., et al. The effect of a probiotic blend on gastrointestinal symptoms in constipated patients: a double blind, randomised, placebo controlled 2-week trial. Benef Microbes. 2019 May 27:1-12. doi: 10.3920/BM2018.0163.
  56. Morovic W., Roper J.M., Smith A.B., et al. Safety evaluation of HOWARU® Restore (Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium animalis subsp. lactis Bl-04 and B. lactis Bi-07) for antibiotic resistance, genomic risk factors, and acute toxicity. Food Chem Toxicol. 2017 Dec;110:316–24. doi: 10.1016/j.fct.2017.10.037.
  57. Morovic W., Roos P., Zabel B., et al. Transcriptional and Functional Analysis of Bifidobacterium animalis subsp. lactis Exposure to Tetracycline. Appl Environ Microbiol. 2018;84(23). pii: e01999-18. doi: 10.1128/AEM.01999-18. Print 2018 Dec 1.
  58. Martinez F.A., Dominguez J.M., Converti A., Oliveira R.P. Production of bacteriocin-like inhibitory substance by Bifidobacterium lactis in skim milk supplemented with additives. J Dairy Res. 2015;82(3):350–55. doi: 10.1017/S0022029915000163.
  59. Paineau D., Carcano D., Leyer G., et al. Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. FEMS Immunol Med Microbiol. 2008;53(1):107–13. doi: 10.1111/j.1574-695X.2008.00413.x.
  60. Guandalini S., Pensabene L., Zikri M.A., et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr. 2000;30(1):54–60. doi: 10.1097/00005176-200001000-00018
  61. Rosenfeldt V., Michaelsen K.F., Jakobsen M., et al. Effect of probiotic Lactobacillus strains in young children hospitalized with acute diarrhea. Pediatr Infect Dis J. 2002;21(5):411–16. doi: 10.1097/00006454-200205000-00012.
  62. Teran C.G., Teran-Escalera C.N., Villarroel P. Nitazoxanide vs. probiotics for the treatment of acute rotavirus diarrhea in children: a randomized, single-blind, controlled trial in Bolivian children. Int J Infect Dis. 2009;13(4):518–23. doi: 10.1016/j.ijid.2008.09.014.
  63. Liu F., Wen K., Li G., et al. Dual functions of Lactobacillus acidophilus NCFM as protection against rotavirus diarrhea. J Pediatr Gastroenterol Nutr. 2014;58(2):169–76. doi: 10.1097/MPG.0000000000000197.
  64. West N.P., Horn P.L., Pyne D.B., et al. Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals. Clin Nutr. 2014;33(4):581–87. doi: 10.1016/j.clnu.2013.10.002.
  65. Turner R.B., Woodfolk J.A., Borish L., et al. Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection – a randomised controlled trial. Benef Microbes. 2017;8(2):207–15. doi: 10.3920/BM2016.0160.
  66. D’Souza A.L., Rajkumar C., Cooke J., Bulpitt C.J. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ. 2002;324(7350):1361. doi: 10.1136/bmj.324.7350.1361.
  67. Paineau D., Carcano D., Leyer G., et al. Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. FEMS Immunol Med Microbiol. 2008;53(1):107–13. doi: 10.1111/j.1574-695X.2008.00413.x.
  68. Del Popolo G., Nelli F. Recurrent bacterial symptomatic cystitis: A pilot study on a new natural option for treatment. Arch Ital Urol Androl. 2018;90(2):101–3. doi: 10.4081/aiua.2018.2.101.
  69. Artanti D., Sari Y.E.S., Azizah F., et al. Effect of giving probiotic supplement Lactobacillus acidophilus La-14 as an immunomodulator to maintain a respiratory system in Mus musculus. Iran J Microbiol. 2021;13(3):381–88. doi: 10.18502/ijm.v13i3.6401.
  70. Todorov S.D., Furtado D.N., Saad S.M., et al. Bacteriocin production and resistance to drugs are advantageous features for Lactobacillus acidophilus La-14, a potential probiotic strain. New Microbiol. 2011;34(4):357–70.
  71. Schlievert P.M., Gaitan A.V., Kilgore S.H., et al. Inhibition of Toxic Shock Syndrome-Associated Staphylococcus aureus by Probiotic Lactobacilli. Microbiol Spectr. 2023 Jul 5:e0173523. doi: 10.1128/spectrum.01735-23.
  72. De Alberti D., Russo R., Terruzzi F., et al. Lactobacilli vaginal colonisation after oral consumption of Respecta(®) complex: a randomised controlled pilot study. Arch Gynecol Obstet. 2015;292(4):861–67. doi: 10.1007/s00404-015-3711-4.
  73. Jang S.E., Jeong J.J., Choi S.Y., et al. Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 Attenuate Gardnerella vaginalis-Infected Bacterial Vaginosis in Mice. Nutrients. 2017;9(6). pii: E531. doi: 10.3390/nu9060531.
  74. Bendazzoli C., Turroni S., Gotti R., et al. Determination of oxalyl-coenzyme A decarboxylase activity in Oxalobacter formigenes and Lactobacillus acidophilus by capillary electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;854(1–2):350–56. doi: 10.1016/j.jchromb.2007.04.027.
  75. Giardina S., Scilironi C., Michelotti A., et al. In vitro anti-inflammatory activity of selected oxalate-degrading probiotic bacteria: potential applications in the prevention and treatment of hyperoxaluria. J Food Sci. 2014;79(3):M384–90. doi: 10.1111/1750-3841.12344.
  76. Szajewska H., Kolodziej M. Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment. Pharmacol. Ther. 2015;42(10):1149–57. doi: 10.1111/apt.13404.
  77. Vale G.C., Mayer M.P.A. Effect of probiotic Lactobacillus rhamnosus by-products on gingival epithelial cells challenged with Porphyromonas gingivalis. Arch Oral Biol. 2021;128:105174. doi: 10.1016/j.archoralbio.2021.105174.
  78. Kelly G. Inulin-type prebiotics--a review: part 1. Altern Med Rev. 2008;13(4):315–29.
  79. Mensink M.A., Frijlink H.W., van der Voort Maarschalk K., Hinrichs W.L. Inulin, a flexible oligosaccharide. II: Review of its pharmaceutical applications. Carbohydr Polym. 2015;134:418–28. doi: 10.1016/j.carbpol.2015.08.022.
  80. Shoaib M., Shehzad A., Omar M., et al. Inulin: Properties, health benefits and food applications. Carbohydr Polym. 2016;147:444–54. doi: 10.1016/j.carbpol.2016.04.020.
  81. Scott J.M., Molloy A.M. The discovery of vitamin B(12). Ann Nutr Metab. 2012;61(3):239–45. doi: 10.1159/000343114.
  82. Pan Y., Liu Y., Guo H., et al. Associations between Folate and Vitamin B12 Levels and Inflammatory Bowel Disease: A Meta-Analysis. Nutrients. 2017;9(4). pii: E382. doi: 10.3390/nu9040382.
  83. Ших Е.В., Соловьева С.А., Перков А.В. Синергизм компонентов как основной подход к формированию пробиотического комплекса. Медицинский совет. 2020;(5):120–27. [Shikh E.V., Solovyova S.A., Perkov A.V. Synergy of components as the main approach to the formation of a probiotic complex. Meditsinskii sovet. 2020;(5):120–27. (In Russ.)]. doi: 10.21518/2079-701X-2020-5-120-127.
  84. Трухан Д.И., Викторова И.А., Иванова Д.С. Синдром диареи в реальной клинической практике: актуальные аспекты дифференциальной диагностики и коррекции. Терапия. 2020; 2(36):145–55. [Trukhan D.I., Viktorova I.A., Ivanova D.S. Diarrhea syndrome in real clinical practice: current aspects of differential diagnosis and correction. Therapy. 2020; 2(36):145–55. (In Russ.)]. doi: 10.18565/therapy.2020.2.145–55.
  85. Славко Е.А., Желдыбаева А.Е. Применение синбиотиков в комплексной терапии заболеваний с синдромом избыточного бактериального роста. Лечение и профилактика. 2022;4:85–9. [Slavko E.A., Zheldybaeva A.E. The use of synbiotics in complex therapy of diseases with bacterial overgrowth syndrome. Lechenie i profilaktika. 2022;4:85–9. (In Russ.)].
  86. Тарасюк А.В., Коньков С.В. Использование синбиотиков в комплексной интенсивной терапии пациентов, находящихся в ОАРИТ. Рецепт. 2022;6:857–64. [Tarasyuk A.V., Konkov S.V. The use of synbiotics in complex intensive care of patients in the intensive care unit. Retsept. 2022;6:857–64. (In Russ.)]. doi: 10.34883/PI.2022.25.6.002
  87. Лазебник Л.Б., Сарсенбаева А.С., Авалуева Е.Б. др. Клинические рекомендации «Хронические диареи у взрослых». Экспериментальная и клиническая гастроэнтерология. 2021;188(4):7–67. [Lazebnik L.B., Sarsenbaeva A.S., Avalueva E.B., et al. Clinical guidelines “Chronic diarrhea in adults”. Eksperimental’naya i klinicheskaya gastroenterologiya. 2021;188(4):7–67. (In Russ.)]. doi: 10.31146/1682-8658-ecg-188-4-7-67.
  88. Ардатская М.Д., Анучкин А.А., Буторова Л.И. др. Патогенетические аспекты развития и лечения антибиотик-ассоциированной диареи: выбор синбиотика с позиции доказательной медицины. Медицинский совет. 2023;6:113–25. [Ardatskaya M.D., Anuchkin A.A., Butorova L.I. et al. Pathogenetic aspects of the development and treatment of antibiotic-associated diarrhea: the choice of synbiotic from the position of evidence-based medicine. Meditsinskii sovet. 2023;6:113–25. (In Russ.)]. doi: 10.21518/ms2023-026.
  89. Пахомова И.Г. Современные возможности повышения эффективности эрадикационной терапии на клиническом примере. Медицинский совет. 2022;16(15):28–34. [Pakhomova I.G. Modern possibilities for increasing the effectiveness of eradication therapy using a clinical example. Meditsinskii sovet. 2022;16(15):28–34. (In Russ.)]. doi: 10.21518/2079-701X-2022-1615-28-34.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies